S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 398.5 JPY -0.39%
Market Cap: 2.1T JPY

Net Margin
Shionogi & Co Ltd

38.9%
Current
38%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
38.9%
=
Net Income
170.4B
/
Revenue
438.3B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
Shionogi & Co Ltd
TSE:4507
2T JPY
39%
US
Eli Lilly and Co
NYSE:LLY
699.1B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
373.4B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
35%
CH
Roche Holding AG
SIX:ROG
211.1B CHF
14%
CH
Novartis AG
SIX:NOVN
186.4B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP
14%
US
Merck & Co Inc
NYSE:MRK
193.3B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
133.5B USD
13%

Shionogi & Co Ltd
Glance View

Market Cap
2T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 021.65 JPY
Overvaluation 16%
Intrinsic Value
Price
S
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
38.9%
=
Net Income
170.4B
/
Revenue
438.3B
What is the Net Margin of Shionogi & Co Ltd?

Based on Shionogi & Co Ltd's most recent financial statements, the company has Net Margin of 38.9%.

Back to Top